Korean J Urol.  1999 Oct;40(10):1301-1304.

Effect of Finasteride on Free/Total Serum PSA Ratio in Patients with Benign Prostate Hyperplasia

• Nam HC
• Kang GM
• Kwon TG
• Park YK

Abstract

PURPOSE: Finasteride, a 5-alpha reductase inhibitor, has recently been used as a treatment for men with benign prostate hyperplasia(BPH). This study was undertaken to determine whether free-to-total(f/t) PSA ratio changed during the finasteride therapy in patient with BPH and whether it is possible to use this new discriminant ratio after prolonged treatment with finasteride.
MATERIALS AND METHODS
The study comprised 31 men (mean age 66 years) with finasteride therapy for BPH. Blood samples were taken before and after 3-13months of therapy with finasteride and f/t PSA ratio is determined using radioimmunometric assay.
RESULTS
Although the mean t-PSA, f-PSA are significantly decreased after the treatment with finasteride, f/t PSA ratio remained unchanged. The duration of treatment and the level of initial t-PSA did not affect the f/t PSA ratio.
CONCLUSIONS
The f/t PSA ratio is unchanged among the patients with finasteride therapy for BPH.

Keyword

Finasteride; Benign prostatic hyperplasia; Prostate cancer; f/t PSA ratio

MeSH Terms

Finasteride*
Humans
Hyperplasia*
Male
Oxidoreductases
Prostate*
Prostatic Hyperplasia
Prostatic Neoplasms
Finasteride
Oxidoreductases